Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.
| 1.24 | |
| 1.09 | |
| - | |
| 1.255 | |
| 1.08 | |
| 0.61-12.5 | |
| 5 598 K | |
| 5 089 K | |
| 33 250 K | |
| -2.88 | |
| 0.447 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
WOBURN, Mass., Dec. 16, 2022 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI), a biopharmaceutical company specializing in the commercialization of dermatological products, today announced the fi...
In this article, we discuss the 11 best German stocks to buy now. If you want to read about some more best German stocks, go directly to the 5 Best German Stocks to Buy Now. Germany is the largest ec...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
